Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych CASC / OSCEPsychopharmacology — renal and hepatic disease

Psych CASC / OSCE · Psychopharmacology — renal and hepatic disease

Explaining psychotropic choices in CKD and cirrhosis (CASC)

CASC-style communication station: organ-aware lithium safety, NSAID counselling, benzodiazepine HE risk, and CAST-informed shared decision on antidepressants.

communication
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 58-year-old woman with bipolar disorder (lithium responder), stage 3b CKD (eGFR 42), and compensated cirrhosis asks why her GP stopped ibuprofen, why you will not give ‘normal sleeping tablets’, and whether her new low mood means she ‘needs sertraline like everyone else on dialysis forums’.

Station instructions (candidate)

You have 7 minutes. Explain in plain language why lithium needs kidney monitoring and why anti-inflammatory painkillers can raise lithium levels; why standard sleeping tablets (benzodiazepines) are risky with her liver disease; and how decisions about antidepressants in kidney disease are individualised — including that a major trial (CAST) found sertraline no better than placebo for depression symptoms in non-dialysis CKD, so expectations and non-drug options matter. Do not terrify her into stopping lithium without a plan. Do not promise cure. Check understanding and safety (suicide risk, who to call if confused or very unsteady).[1][2][3][5]

Marking domains

Empathy and agenda setting; accurate lithium–kidney and NSAID counselling; HE-aware benzodiazepine advice; CAST-informed shared decision without therapeutic nihilism; collaborative monitoring plan; safety-netting for toxicity and mood risk.[1][2][3][4]

Model communication map

  1. Open: thank her; name the three worries (painkiller, sleep tablets, antidepressant); check mood and safety.[5]
  2. Lithium and kidneys: lithium is cleared by the kidneys; we watch blood levels and kidney tests because levels can creep up when kidneys work less well or when dehydrated.[2][4]
  3. Ibuprofen: anti-inflammatory painkillers can push lithium higher — that is why GP stopped them; prefer agreed alternatives and always ask before new pharmacy medicines.[2]
  4. Sleep tablets: with liver disease, strong sedatives can tip people into confusion (encephalopathy); we avoid routine benzodiazepines and use safer sleep strategies first; if a medicine is ever essential it would be a carefully chosen short course at low dose.[3][6]
  5. Low mood / sertraline: depression is common and treatable with support; CAST showed sertraline was not better than placebo for symptoms in people with kidney disease not on dialysis and had more stomach side-effects — so we decide together, may still trial a medicine carefully, and always include talking therapies and safety planning.[1][5]
  6. Close: written sick-day rules, next blood test date, crisis contacts, symptoms needing urgent review (coarse tremor, confusion, severe unsteadiness, yellowing of eyes).[2]

Common fails

  • Ordering her off lithium without explaining benefit and monitoring.[4]
  • Agreeing to regular diazepam for cirrhosis insomnia.[3]
  • Claiming “sertraline always works in CKD” contrary to CAST teaching.[1]
  • Omitting suicide/safety assessment for new depression.[5]
  • Using jargon (EXTRIP, free fraction) without plain-language translation.[2]

References

  1. [1]Hedayati SS, Gregg LP, Carmody T, et al. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial JAMA, 2017.PMID 29101402
  2. [2]Gitlin M Lithium side effects and toxicity: prevalence and management strategies Int J Bipolar Disord, 2016.PMID 27900734
  3. [3]Grønbæk L, Watson H, Vilstrup H, et al. Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites United European Gastroenterol J, 2018.PMID 29774154
  4. [4]McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis Lancet, 2012.PMID 22265699
  5. [5]Hedayati SS, Yalamanchili V, Finkelstein FO A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease Kidney Int, 2012.PMID 22012131
  6. [6]Telles-Correia D, Barbosa A, Cortez-Pinto H, et al. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity World J Gastrointest Pharmacol Ther, 2017.PMID 28217372